SBFM Overview

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.

Wall Street analysts forecast SBFM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SBFM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sunshine Biopharma Inc revenue for the last quarter amounts to 8.09M USD, decreased -9.13

Sunshine Biopharma Inc. EPS for the last quarter amounts to -2.54 USD, decreased -41.74

Sunshine Biopharma Inc (SBFM) has 50 emplpoyees as of June 15 2026.

Today SBFM has the market capitalization of 4.71M USD.